ID

31773

Beschrijving

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT00390221

Link

https://clinicaltrials.gov/show/NCT00390221

Trefwoorden

Versies (1)
  1. 27-09-18 27-09-18 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

27 september 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00390221

Engels

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00390221

1 Formulieren  
Criteria
Beschrijving

Criteria

multiple sclerosis (ms) subjects who have a confirmed diagnosis of relapsing-remitting ms according to mcdonald criteria #1-4 and a baseline expanded disability status scale (edss) between 0.0 and 5.0, inclusive, who meet either of the following 2 criteria
Beschrijving

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | EDSS

Datatype

boolean

Alias
UMLS CUI [1]
C0026769
UMLS CUI [2]
C0751967
UMLS CUI [3]
C0451246
have experienced at least 1 relapse within the 12 months prior to randomization, with a cranial magnetic resonance imaging (mri) demonstrating lesion(s) consistent with ms , or
Beschrijving

Relapse Quantity | Lesion Consistent with Multiple Sclerosis | MRI Cranium

Datatype

boolean

Alias
UMLS CUI [1,1]
C0035020
UMLS CUI [1,2]
C1265611
UMLS CUI [2,1]
C0221198
UMLS CUI [2,2]
C0332290
UMLS CUI [2,3]
C0026769
UMLS CUI [3,1]
C0024485
UMLS CUI [3,2]
C0037303
show evidence of gadolinium-enhancing lesions of the brain on an mri performed within the 6 weeks prior to randomization.
Beschrijving

Lesion of brain Nuclear magnetic resonance imaging gadolinium-enhanced

Datatype

boolean

Alias
UMLS CUI [1,1]
C0221505
UMLS CUI [1,2]
C0855566
key exclusion criteria:
Beschrijving

Exclusion Criteria Main

Datatype

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
diagnosis of primary progressive, secondary progressive, or progressive relapsing ms
Beschrijving

Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Progressive Relapsing

Datatype

boolean

Alias
UMLS CUI [1]
C0751964
UMLS CUI [2]
C0751965
UMLS CUI [3]
C0393666
history of malignancy
Beschrijving

Malignant Neoplasms

Datatype

boolean

Alias
UMLS CUI [1]
C0006826
history of severe allergic or anaphylactic reactions or known drug hypersensitivity
Beschrijving

Severe allergic reaction | Anaphylaxis Severe | Drug Allergy

Datatype

boolean

Alias
UMLS CUI [1]
C2220378
UMLS CUI [2,1]
C0002792
UMLS CUI [2,2]
C0205082
UMLS CUI [3]
C0013182
history of abnormal laboratory results
Beschrijving

Laboratory test result abnormal

Datatype

boolean

Alias
UMLS CUI [1]
C0438215
history of human immunodeficiency virus (hiv) or other immunodeficient conditions
Beschrijving

HIV Infection | Immunodeficiency

Datatype

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0021051
history of drug or alcohol abuse within the 2 years prior to randomization
Beschrijving

Substance Use Disorders

Datatype

boolean

Alias
UMLS CUI [1]
C0038586
an ms relapse that has occurred within the 50 days prior to randomization and/or the subject has not stabilized from a previous relapse prior to randomization
Beschrijving

Multiple sclerosis relapse | Relapse Previous Without Stabilization

Datatype

boolean

Alias
UMLS CUI [1]
C0856120
UMLS CUI [2,1]
C0035020
UMLS CUI [2,2]
C0205156
UMLS CUI [2,3]
C0332288
UMLS CUI [2,4]
C1293130
positive screening for active infection with hepatitis b virus or hepatitis c virus
Beschrijving

Hepatitis B positive | Hepatitis C positive

Datatype

boolean

Alias
UMLS CUI [1]
C0856706
UMLS CUI [2]
C1112419
varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before screening
Beschrijving

Varicella Zoster Virus Infection | Herpes zoster infection | Viral infection severe

Datatype

boolean

Alias
UMLS CUI [1]
C0586989
UMLS CUI [2]
C0019360
UMLS CUI [3,1]
C0042769
UMLS CUI [3,2]
C0205082
exposure to varicella zoster virus within 21 days before screening.
Beschrijving

Exposure to Varicella zoster virus

Datatype

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0042338
abnormal blood tests at screening; hemoglobin ≤9.0 g/dl, platelets ≤100 × 109/l, lymphocytes ≤1.0 × 109/l, neutrophils ≤1.5 × 109/l, alanine aminotransferase/serum glutamate pyruvate transaminase (alt/sgpt), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (ast/sgot), or gamma-glutamyl-transferase >2 times the upper limit of normal (uln) and serum creatinine >uln.
Beschrijving

Abnormal blood test | Hemoglobin measurement | Platelet Count measurement | Lymphocyte Count measurement | Neutrophil count | Alanine aminotransferase increased | Aspartate aminotransferase increased | Gamma-glutamyl transferase raised | Serum creatinine raised

Datatype

boolean

Alias
UMLS CUI [1]
C0854146
UMLS CUI [2]
C0518015
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0200635
UMLS CUI [5]
C0200633
UMLS CUI [6]
C0151905
UMLS CUI [7]
C0151904
UMLS CUI [8]
C0151662
UMLS CUI [9]
C0700225
note: other protocol defined inclusion/exclusion criteria may apply.
Beschrijving

Eligibility Criteria Study Protocol

Datatype

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Terug naar het begin van de pagina

Similar models

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00390221

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | EDSS
Item
multiple sclerosis (ms) subjects who have a confirmed diagnosis of relapsing-remitting ms according to mcdonald criteria #1-4 and a baseline expanded disability status scale (edss) between 0.0 and 5.0, inclusive, who meet either of the following 2 criteria
boolean
C0026769 (UMLS CUI [1])
C0751967 (UMLS CUI [2])
C0451246 (UMLS CUI [3])
Relapse Quantity | Lesion Consistent with Multiple Sclerosis | MRI Cranium
Item
have experienced at least 1 relapse within the 12 months prior to randomization, with a cranial magnetic resonance imaging (mri) demonstrating lesion(s) consistent with ms , or
boolean
C0035020 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0221198 (UMLS CUI [2,1])
C0332290 (UMLS CUI [2,2])
C0026769 (UMLS CUI [2,3])
C0024485 (UMLS CUI [3,1])
C0037303 (UMLS CUI [3,2])
Lesion of brain Nuclear magnetic resonance imaging gadolinium-enhanced
Item
show evidence of gadolinium-enhancing lesions of the brain on an mri performed within the 6 weeks prior to randomization.
boolean
C0221505 (UMLS CUI [1,1])
C0855566 (UMLS CUI [1,2])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Progressive Relapsing
Item
diagnosis of primary progressive, secondary progressive, or progressive relapsing ms
boolean
C0751964 (UMLS CUI [1])
C0751965 (UMLS CUI [2])
C0393666 (UMLS CUI [3])
Malignant Neoplasms
Item
history of malignancy
boolean
C0006826 (UMLS CUI [1])
Severe allergic reaction | Anaphylaxis Severe | Drug Allergy
Item
history of severe allergic or anaphylactic reactions or known drug hypersensitivity
boolean
C2220378 (UMLS CUI [1])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0013182 (UMLS CUI [3])
Laboratory test result abnormal
Item
history of abnormal laboratory results
boolean
C0438215 (UMLS CUI [1])
HIV Infection | Immunodeficiency
Item
history of human immunodeficiency virus (hiv) or other immunodeficient conditions
boolean
C0019693 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
Substance Use Disorders
Item
history of drug or alcohol abuse within the 2 years prior to randomization
boolean
C0038586 (UMLS CUI [1])
Multiple sclerosis relapse | Relapse Previous Without Stabilization
Item
an ms relapse that has occurred within the 50 days prior to randomization and/or the subject has not stabilized from a previous relapse prior to randomization
boolean
C0856120 (UMLS CUI [1])
C0035020 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0332288 (UMLS CUI [2,3])
C1293130 (UMLS CUI [2,4])
Hepatitis B positive | Hepatitis C positive
Item
positive screening for active infection with hepatitis b virus or hepatitis c virus
boolean
C0856706 (UMLS CUI [1])
C1112419 (UMLS CUI [2])
Varicella Zoster Virus Infection | Herpes zoster infection | Viral infection severe
Item
varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before screening
boolean
C0586989 (UMLS CUI [1])
C0019360 (UMLS CUI [2])
C0042769 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
Exposure to Varicella zoster virus
Item
exposure to varicella zoster virus within 21 days before screening.
boolean
C0332157 (UMLS CUI [1,1])
C0042338 (UMLS CUI [1,2])
Abnormal blood test | Hemoglobin measurement | Platelet Count measurement | Lymphocyte Count measurement | Neutrophil count | Alanine aminotransferase increased | Aspartate aminotransferase increased | Gamma-glutamyl transferase raised | Serum creatinine raised
Item
abnormal blood tests at screening; hemoglobin ≤9.0 g/dl, platelets ≤100 × 109/l, lymphocytes ≤1.0 × 109/l, neutrophils ≤1.5 × 109/l, alanine aminotransferase/serum glutamate pyruvate transaminase (alt/sgpt), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (ast/sgot), or gamma-glutamyl-transferase >2 times the upper limit of normal (uln) and serum creatinine >uln.
boolean
C0854146 (UMLS CUI [1])
C0518015 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0200635 (UMLS CUI [4])
C0200633 (UMLS CUI [5])
C0151905 (UMLS CUI [6])
C0151904 (UMLS CUI [7])
C0151662 (UMLS CUI [8])
C0700225 (UMLS CUI [9])
Eligibility Criteria Study Protocol
Item
note: other protocol defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial